---
document_datetime: 2024-09-12 11:09:10
document_pages: 15
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/resolor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: resolor-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 12.3044922
conversion_datetime: 2025-12-20 15:52:23.767201
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Resolor

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/2568/ 202310   | Periodic Safety Update EU Single assessment - prucalopride                                                                                                                                                                                                                                                           | 13/06/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |
| IA/0059/G            | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold | 31/07/2023                          | n/a                                         |                                  |                                   |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | increase compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                        |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| IA/0058/G          | This was an application for a group of variations. B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.d.1.a.1 - Stability of AS - Change in the re-test period/storage period - Reduction                                                                                                                                        | 31/07/2023 | n/a        |                        |                                   |
| IAIN/0057          | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                     | 14/12/2022 | 29/11/2023 | SmPC, Labelling and PL |                                   |
| N/0056             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                               | 19/08/2022 | 16/12/2022 | PL                     |                                   |
| PSUSA/2568/ 202110 | Periodic Safety Update EU Single assessment - prucalopride                                                                                                                                                                                                                                                                                                                                                                                     | 10/06/2022 | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0054/G          | This was an application for a group of variations. B.I.a.1.i - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new site of micronisation B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 21/12/2021 | 16/12/2022 | Annex II and PL        |                                   |

<div style=\"page-break-after: always\"></div>

|         | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                          |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0052 | B.I.a.1.g - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new manufacturer of the AS that is not supported by an ASMF and requires significant update to the relevant AS section in the dossier                                           | 16/09/2021 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| T/0053  | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                    | 13/08/2021 | 15/09/2021 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0051 | Update of the RMP on the patients' exposure based on based on post-marketing reports. In addition, the MAH took the opportunity to make minor editorial changes to the SmPC and RMP. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 25/06/2020 | 17/06/2021 | SmPC                   | The CHMP agreed on the addition of data to the RMP on estimated exposure through the data-lock point of the data review for suicidal ideation and behaviour, including that of the US and on minor editorial changes proposed to the SmPC and RMP. Data provided based on post marketing reports were not considered sufficient evidence to support an association of suicidal ideation and behaviour with exposure to prucalopride and to add a new warning in SmPC and package leaflet. A cumulative review of the nonclinical data, clinical data, the global safety database, relevant literature, and external (regulatory) databases through 14 October 2018 concluded that there is insufficient evidence to support an association of suicidal ideation and behaviour with exposure to prucalopride. The introduction of suicidal ideation and behaviour as an important potential risk in the RMP was similarly not considered to be acceptable. Routine pharmacovigilance activities are considered sufficient to detect a signal on this topic. The CHMP concluded that |

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |     | suicidal ideation and behaviour should continue to be closely monitored and any new cases discussed in the next PSUR.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2568/ 201910 | Periodic Safety Update EU Single assessment - prucalopride                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 11/06/2020 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0049/G          | This was an application for a group of variations. Submission of the final report from study SH555-802 and an independent adjudication on all potential MACE from completed Phase 2/4 clinical studies in adult subjects. This is a non-interventional pharmacoepidemiology safety study with the primary objective to estimate, in real-world settings, the IRR and 95% CI for MACE in initiators of prucalopride compared with initiators of PEG (polyethylene glycol 3350), adjusting for potential confounders. More specifically, the study aimed to investigate whether the upper bound of the two-sided 95% CI for the adjusted IRR was less than 3.00. The study was designed as a multidatabase study with data from Germany, UK and Sweden with pooled results. German data was later discarded since due to disparate clinical profile of German patients C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 27/02/2020 | n/a | The results from study SH555-802 did not provide evidence of an increased risk of MACE overall among patients with chronic constipation using prucalopride. In the post hoc analyses, results were also consistent, except for the small subgroup of men older than 55 years of age with an IRR of 2.57 (95% CI, 0.71-9.26). However, as this subgroup had a very small sample size and thus the finding could very well be due to chance. The overall pooled analyses were consistent with the finding of no evidence of an increased risk of MACE in patients with chronic constipation using prucalopride as compared with PEG. The number of MACE from the clinical studies in subjects with chronic idiopathic constipation were low, no firm conclusion to exclude the risk of MACE can be reached based on the submitted data, however no new safety information is warranted to be included in the product information. The potential risk of MACE events is closely monitored in PSURs. |

<div style=\"page-break-after: always\"></div>

|           | data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0046   | Please refer to the Recommendations section above. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                         | 28/02/2019 | 21/02/2020 | SmPC            | Migraine and vertigo were added to section 4.8 of the SmPC as uncommon adverse events based on reanalysis of the integrated safety information of 16 double-blind, placebo-controlled studies. Section 4.6 has been updated to emphasize that women of childbearing potential have to use effective contraception during treatment with prucalopride. Resolor is not recommended in women of childbearing potential not using contraception. In the absence of human data in women who breast fed while taking Resolor, a decision should be made whether to discontinue breast feeding or to discontinue Resolor therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman. |
| IAIN/0048 | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                   | 22/10/2018 | 31/01/2019 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0042   | Submission of the final clinical study report for the post-authorization drug utilization study SHP555-804 in fulfilment of MEA 006.11, a drug utilisation study to examine characteristics of patients prescribed prucalopride (Resolor) and a pharmacoepidemiological study of the occurrence of major cardiovascular events, pregnancy, and pregnancy outcomes in the UK Clinical Practice Research Database (CPRD). The RMP (v 15.1) has also been updated to reflect the study results. | 06/09/2018 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                    | elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                      |            |            |                        |                                                                                                  |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------|
| PSUSA/2568/ 201710 | Periodic Safety Update EU Single assessment - prucalopride                                                                                                                                                                                                      | 17/05/2018 | n/a        |                        | PRAC Recommendation - maintenance                                                                |
| IAIN/0043          | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                      | 05/02/2018 | 31/01/2019 | SmPC, Labelling and PL |                                                                                                  |
| N/0040             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                | 12/07/2017 | 31/01/2019 | PL                     |                                                                                                  |
| PSUSA/2568/ 201610 | Periodic Safety Update EU Single assessment - prucalopride                                                                                                                                                                                                      | 05/05/2017 | n/a        |                        | PRAC Recommendation - maintenance                                                                |
| PSUSA/2568/ 201510 | Periodic Safety Update EU Single assessment - prucalopride                                                                                                                                                                                                      | 13/05/2016 | n/a        |                        | PRAC Recommendation - maintenance                                                                |
| N/0037             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                | 08/12/2015 | 31/01/2019 | PL                     |                                                                                                  |
| IG/0621            | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                 | 16/10/2015 | n/a        |                        |                                                                                                  |
| II/0034            | Update of the SmPC extending the indication to the male patient population for the treatment of chronic constipation in adults in whom laxatives fail to provide adequate relieve for Resolor. Consequently update of sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and | 23/04/2015 | 27/05/2015 | SmPC and PL            | Please refer to the scientific discussion Resolor EMEA/H/C/001012/II/34 for further information. |

<div style=\"page-break-after: always\"></div>

|                    | 5.2 of the SmPC. The Package Leaflet is updated in accordance. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                                                                                                                                                                                                                                                                                                       |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2568/ 201410 | Periodic Safety Update EU Single assessment - prucalopride                                                                                                                                                                                                                                                                                                                                                                                                                                          | 07/05/2015 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| II/0031            | Update of sections 4.2, 5.1, 5.2 and 5.3 of the SmPC in order to reflect the results of Study M0001-C303 conducted in paediatric patients, aged ≥ 6 months to <18 years and the rat juvenile toxicity study R4488M-SPD555. The Package Leaflet is updated in accordance. Furthermore, the SmPC, Annex II and the PL are updated in line with the latest QRD template version 9.0. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 24/07/2014 | 27/05/2015 | SmPC, Annex II and PL | The efficacy and safety of Resolor in paediatric patients (aged 6 months to 18 years) with functional constipation, were evaluated in Study M0001-C303 which consisted of an 8-week double-blind, placebo-controlled trial, followed by a 16 week open-label comparator-controlled (Polyethylene glycol 4000) study of up to 24 weeks. The results of the study showed no difference in efficacy between Resolor and placebo (P= 0.9002). Overall, the safety profile of prucalopride in children was the same as in adults. Based on the results of this study, the CHMP concluded that Resolor should not be used in children and adolescents younger than 18 years. In addition, in a juvenile toxicity study in immature rats, there was evidence of delay to sexual maturation following exposure to high dose levels of prucalopride. Findings of maturation delay had previously |
| II/0030            | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH                                                                                                                                                                                                                                               | 26/06/2014 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|         | where significant assessment is required                                                                                                                                                                                                                                                                                                                                   |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0027 | Update sections 4.2 and 5.1 of the Summary of Product Characteristic (SmPC) following provision of the results of the SPD555-401 study, a long-term placebo controlled efficacy/safety study of 6 months duration in patients with chronic constipation. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 26/06/2014 | 27/05/2015 | SmPC                   | The efficacy of Resolor beyond three months of treatment has not been demonstrated in placebo-controlled studies. The efficacy and safety of prucalopride in patients (aged ≥ 18 or older) with chronic constipation, were evaluated in a 24 week multicentre, randomised, double-blind, placebo controlled study (N=364). The proportion of patients with an average weekly frequency of ≥ 3 Spontaneous Complete Bowel Movements (SCBMs) per week (ie, responders) over the 24-week double-blind treatment phase was not statistically different (p=0.367) between the prucalopride (25.1%) and placebo (20.7%) treatment groups. The difference between treatment groups in the average weekly frequency of ≥ 3 SCBMs per week was not statistically significant over Weeks 1-12 which is inconsistent with the 3 previous multicentre, randomised, double-blind, 12-week placebo controlled studies demonstrating efficacy at this timepoint in adult patients. The study is therefore considered to be inconclusive with respect to efficacy. However, the totality of the data including the previous double-blind placebo controlled 12 week studies support the efficacy of prucalopride. The safety profile of prucalopride in this 24 week study was consistent with that seen in the previous 12 week studies. |
| R/0032  | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                    | 25/04/2014 | 06/06/2014 | SmPC, Labelling and PL | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of Resolor continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Resolor continues to be favourable in                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |            |                        | the symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief. The CHMP recommends the renewal of the Marketing Authorisation with unlimited validity.   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUV/0033 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 08/05/2014 | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                       |
| IB/0028/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch | 07/02/2014 | n/a        |                        |                                                                                                                                                                                                         |
| IA/0029   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 17/12/2013 | n/a        |                        |                                                                                                                                                                                                         |
| T/0025    | Transfer of Marketing Authorisation from Shire- Movetis N.V to Shire Pharmaceuticals Ireland Limited.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 04/09/2013 | 25/09/2013 | SmPC, Labelling and PL |                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0026    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 22/08/2013 | 25/09/2013 | PL                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IAIN/0024 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 05/06/2013 | 25/09/2013 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0023   | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 27/02/2013 | 25/09/2013 | SmPC                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0022   | Update of section 5.1 of the SmPC in order to add information from the three pivotal trials related to spontaneous bowel movements, specific symptoms associated with constipation, and quality of life. In addition, the MAH took the opportunity to update the list of local representatives and implemented some editorial changes and linguistic corrections in SmPC and Package Leaflet. Furthermore, the MAH proposed this opportunity to bring the PI in line with the latest QRD template version 8.2. The requested variation proposed amendments to the SmPC, Annex II, and Package Leaflet. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 13/12/2012 | 25/09/2013 | SmPC, Annex II and PL  | Additional efficacy results from the integrated three pivotal studies were summarized for spontaneous bowel movements (SBMs), specific symptoms associated with constipation and quality of life data. Prucalopride's effect on SBM proved to be statistically superior to placebo for the portion of patients that had an increase of ≥ 1 SBM/week over the 12-week treatment period. Furthermore details from specific symptom subscales of the PAC-SYM on abdominal (bloating, discomfort, pain, and cramps), stool (incomplete bowel movements, false alarm, straining, too hard, and too small), and rectal symptoms (painful bowel movements, burning, and bleeding/tearing), determined at Week 4 and Week 12 and details on the improvement in the Patient Assessment of Constipation-Quality of Life satisfaction subscale (PAC-QOL) were added to Section 5.1 of the SmPC. |
| IA/0021   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 19/09/2012 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

|           | procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0216   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                         | 14/09/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IAIN/0019 | B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacturer                                                                                                                                                                                                                                                                                         | 20/06/2012 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| II/0013   | Update of sections 4.2., 4.4. and 5.2 of the SmPC in order to update the safety information regarding the use in patients with hepatic impairment . In addition, the MAH took the opportunity to introduce some editorial changes to the SmPC and Package Leaflet. The requested variation proposed amendments to the SmPC and Package Leaflet. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 16/02/2012 | 19/03/2012 | SmPC and PL | Study M00001-C103 was an open-label, single dose, parallel group pharmacokinetic study to assess the pharmacokinetics of prucalopride 2mg in patients with impaired hepatic function (moderate (Child Pugh Grade B) and severe (Grade C)) compared with healthy subjects with normal hepatic function. In this small pharmacokinetic study the Cmax and AUC of prucalopride were, on average, 10-20% higher in patients with moderate to severe hepatic impairment compared with healthy subjects. However, the majority of patients included in this study categorised as having severe hepatic impairment had relatively low Child Pugh scores. Therefore it cannot be excluded that severe hepatic impairment significantly influences significantly prucalopride blood levels. The results of this study were included in the SmPC. Furthermore, the CHMP considered that based on the available data the starting dose for patients with severe hepatic impairment should remain 1 mg once daily and that the response should be evaluated before deciding whether to increase the dose. |
| II/0014   | Update of section 5.1 of the SmPC in order to focus                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 19/01/2012 | 23/02/2012 | SmPC, Annex | The efficacy results from the pooled Phase 3 pivotal studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | the reported efficacy results from the pooled Phase 3 pivotal studies on the approved female-only population. Furthermore, the PI is being brought in line with the latest QRD template version 8.0. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                |            |            | II, Labelling and PL   | (males and females) mentioned in 5.1 of the SmPC were replaced by the efficacy results of these studies on the population targeted in this label (females).                                                                                                                                                                                                       |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0016   | Update of section 4.5 of the SmPC in order to update the safety information adding oral contraceptives to the list of drugs with no interaction resulting from a drug interaction study with oral contraceptives (fulfilled FUM 002). In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data | 15/12/2011 | 30/01/2012 | SmPC and PL            | Clinical study M0001-C101 demonstrated a lack of effect both during a single dose and steady state administration of prucalopride (at the clinically recommended doses) on the pharmacokinetics and pharmacodynamics of oral contraceptives. Further to these results, oral contraceptives were added to the list of drugs with no interaction with prucalopride. |
| IB/0018   | B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation                                                                                                                                                                                                                                                                                                                                                                                          | 03/01/2012 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0015   | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                    | 24/10/2011 | n/a        | SmPC                   | - to increase the shelf life of the finished product from 36 to 48 months based on extrapolation of 36 months data in accordance with ICH guideline                                                                                                                                                                                                               |
| IA/0012/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 19/04/2011 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|           | C.I.9.d - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the safety database C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system   |            |     |                                  |                                                                                                                                                                                                                                                                                       |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0011    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                            | 17/03/2011 | n/a | PL                               | Inclusion of the list of local representatives at the end of the package leaflet.                                                                                                                                                                                                     |
| IB/0010   | C.I.8.b - Introduction of a new Pharmacovigilance system - which has been assessed by the relevant NCA/EMA for another product of the same MAH                                                                                                                                                              | 10/03/2011 | n/a |                                  | Implementation of existing Shire DDPS.                                                                                                                                                                                                                                                |
| IA/0009   | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                  | 19/01/2011 | n/a | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                       |
| IB/0008   | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                  | 15/12/2010 | n/a | SmPC and PL                      | Update of section 4.2 and 4.4 to strengthen that Resolor is not recommended for use in men as data for this patient population are currently unavailable as requested by the CHMP following the assessment of the Risk Management Plan version 4.0 (RMP 013) dated 28 September 2010. |
| IB/0007/G | This was an application for a group of variations. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary                                                              | 05/10/2010 | n/a | Annex II and PL                  |                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

|           | or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.b.2 - Change to batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.3.a - Change in the manufacturing process of the finished product - Minor change in the manufacturing process of an immediate release solid oral dosage form or oral solutions   |            |            |                        | B.II.b.1.b - Replacement   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------|
| IB/0006   | B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other                                                                                                                                                                                                                                                                                                                                                                                  | 05/10/2010 | n/a        | SmPC                   | variation                  |
| IA/0005   | C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD                                                                                                                                                                                                                                     | 09/09/2010 | n/a        | Annex II               |                            |
| IB/0002/G | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished                                                                                                                                                                                      | 30/07/2010 | 30/07/2010 | SmPC, Labelling and PL |                            |

<div style=\"page-break-after: always\"></div>

|         | product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside   |            |     |                        |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------------------------|
| IA/0004 | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 08/07/2010 | n/a | SmPC, Labelling and PL |
| IB/0001 | IB_14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 05/01/2010 | n/a |                        |